



## Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)

Registered Office:

3<sup>rd</sup> Floor, Srivalli's Corporate, Plot No.290, Road No.6,  
Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills,  
Hyderabad, Shaikpet, Telangana, India-500033

T: +91 40 23635000, E:info@viyash.com

E: investorrelations@viyash.com

Website: www.viyash.com

CIN: L99999TS1985PLC196357

February 05, 2026

To,

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001

**National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra-Kurla Complex,  
Bandra (East),  
Mumbai - 400 051

**Scrip code: 512529**

**Scrip code: VIYASH**

**Subject: Outcome of Board Meeting held on Thursday, February 05, 2026, along with Unaudited Standalone & Consolidated Financial Results for the quarter and nine months ended December 31, 2025.**

Dear Sir/ Madam,

We refer to our letter dated January 21, 2026, regarding the meeting of the Board of Directors (“**Board**”) of the Company scheduled to be held on Thursday, February 05, 2026 and in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 (“**SEBI Listing Regulations**”), we hereby inform you that the Board at its meeting held today i.e., February 05, 2026, has, *inter alia*, transacted the following businesses:

1. Considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025:

Accordingly, Unaudited Financial Results (Standalone and Consolidated) along with Independent Auditor’s Limited Review Report pursuant to Regulation 33 of the SEBI Listing Regulations read with applicable SEBI circular(s) are enclosed herewith for your information.

2. In terms of the Composite Scheme of Amalgamation, based on the recommendations of the Nomination and Remuneration Committee, the Board, has approved introduction and adoption of new employee stock option scheme namely “Viyash Scientific Limited Employee Stock Option Scheme 2026” (“**VSL ESOP Scheme 2026**”), subject to necessary approvals, as may be applicable.

Details Required as per SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed in **Annexure I**.

3. Considered and approved changes in Senior Management Personnel (“**SMP**”) of the Company.

Pursuant to regulation 30 read with Schedule III of the SEBI Listing Regulations, based on the recommendation of the Nomination and Remuneration Committee (“**NRC**”), the Board has considered and approved changes in the SMPs of the Company based on the comprehensive review of leadership roles to align with the post-merger strategic objectives and operational requirements.



## Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)

Registered Office:

3<sup>rd</sup> Floor, Srivalli's Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033

T: +91 40 23635000, E:[info@viyash.com](mailto:info@viyash.com)

E: [investorrelations@viyash.com](mailto:investorrelations@viyash.com)

Website: [www.viyash.com](http://www.viyash.com)

CIN: L99999TS1985PLC196357

Consequent to the aforesaid organizational changes, the following employees, are designated as SMPs w.e.f. February 5, 2026:

| Sr No. | Name                                    | Designation                                |
|--------|---|--|
| 1      | Mr. Attanti Veera Venkata Srinivasa Rao | VP, R&D (API)                              |
| 2      | Mr. Nrusimha Srinivasa Rao Bondalapati  | VP, Quality & Regulatory                   |
| 3      | Mr. Peddanna Gumudavelli                | COO, Appco Pharma LLC, Material Subsidiary |

Also, following employee who was previously designated as SMP, shall cease to be SMP w.e.f. February 5, 2026, although continuing to be employed with the Company in their respective role:

| Sr No. | Name                 | Designation            |
|--------|----------------------|------------------------|
| 1      | Mr. Pradip Natarajan | AVP, Quality Assurance |

Further, the details as required in terms of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed as **Annexure II** to this intimation.

4. Pursuant to Regulation 30(5) of the SEBI LODR, contact details of the Directors/Key Managerial Personnel who are authorized to determine materiality of event/information for the purpose of making disclosures to the stock exchange(s), are as under:

| Sr No. | Name                  | Designation  | Email id and contact   | Authorisation   |
|--------|-----------------------|--|--|---|
| 1      | Dr. Haribabu Bodepudi | Managing Director and group CEO                    | <a href="mailto:investorrelations@sequent.in">investorrelations@sequent.in</a><br>T: +91 40 23635000 | Determine materiality of event/information                                  |
| 2.     | Mr. Rajaram Narayanan | Whole-time Director and CEO Animal Health Business |  |   |
| 3.     | Mr. Ramakant Singani  | Chief Financial Officer                            |  | Determine materiality of event/information and Disclosure to Stock Exchange |
| 4.     | Ms. Yoshita Vora      | Company Secretary                                  |  | Disclosure to Stock Exchange  |

The Board Meeting commenced at 7:00 p.m. and concluded at 08:12 p.m.

**Yours faithfully,**

**For Viyash Scientific Limited**

*(Formerly known as Sequent Scientific Limited)*

**Yoshita Vora**

**Company Secretary & Compliance Officer**

**Encl: A/a**

**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended****Review Report to****The Board of Directors****Viyash Scientific Limited (formerly known as Sequent Scientific Limited)**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Viyash Scientific Limited (formerly known as Sequent Scientific Limited) (the "Holding Company") including Sequent Scientific Employee Stock Option Plan Trust (the "Trust") and its subsidiaries (the Holding Company, Trust and its subsidiaries together referred to as "the Group"), for the quarter ended December 31, 2025 and year to date from April 01, 2025 to December 31, 2025 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure 1 to the auditor's review report.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We draw attention to Note 4 to the accompanying Statement, which describes that pursuant to the Composite Scheme of Amalgamation (the "Scheme") between the Company and SeQuent Research Limited, Viyash Life Sciences Private Limited and its subsidiaries (individually referred to as "Transferor Company"), as approved by the Hon'ble National Company Law Tribunal vide its order dated November 18, 2025, the Transferor Companies have been amalgamated with the Company. The amalgamation has been accounted for in the manner as prescribed under the Scheme and in accordance with Appendix C of Ind AS 103 - Business Combinations, applicable to business combination of entities under common control. Accordingly, the comparative financial information for the quarter ended 30 September 2025,



**Viyash Scientific Limited (formerly known as Sequent Scientific Limited)**  
**Page 2 of 4**

quarter / period ended 31 December 2024 and year ended 31 March 2025 presented in accompanying Statement, has been restated to give effect to the aforesaid amalgamation, as described further in the said note. Our conclusion is not modified in respect of this matter.

7. The accompanying Statement includes the unaudited interim financial results and other unaudited financial information, in respect of:

- Thirteen subsidiaries, whose unaudited interim financial results include total revenues of Rs. 3,542.60 million and Rs. 9,900.40 million, total net profit after tax of Rs. 271.50 million Rs. 882.50 million, total comprehensive income of Rs. 271.50 million and Rs. 882.50 million for the quarter ended December 31, 2025, and the period ended on that date respectively, as considered in the Statement which have been reviewed by their respective independent auditors.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

Certain of these subsidiaries are located outside India whose financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been audited by other auditors under generally accepted auditing standards applicable in their respective countries. The Holding Company's management has converted the financial results of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion in so far as it relates to the balances and affairs of such subsidiaries located outside India is based on the report of other auditors and the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

8. The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of:

- Sequent Scientific Employee Stock Option Plan Trust, whose interim financial results and other financial information reflect total revenues of Rs. Nil and Rs. Nil, total net (loss) / profit after tax of Rs. (0.01 million) and Rs. 0.02 million, total comprehensive (expense) / income of Rs. (0.01 million) and Rs. 0.02 million for the quarter ended December 31, 2025 and period ended on that date respectively and
- Two subsidiaries, whose interim financial results and other financial information reflect total revenues of Rs 40.50 million and Rs. 121.20 million, total net profit after tax of Rs. 4.20 million and Rs. 2.60 million, total comprehensive income of Rs. 4.20 million and Rs. 2.60 million, for the quarter ended December 31, 2025 and the period ended to that date respectively.

The unaudited interim financial results and other unaudited financial information of the Trust and these subsidiaries have not been reviewed by any auditor and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries, is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement in respect of matters stated in para 7 and 8 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Management.



# **S R B C & CO LLP**

Chartered Accountants

## **Viyash Scientific Limited (formerly known as Sequent Scientific Limited)**

**Page 3 of 4**

9. The comparative Ind AS financial information presented in the accompanying Statement includes the financial information of Viyash Life Sciences Private Limited and its subsidiaries for the quarter / period ended 31 December 2024 and for the year ended 31 March 2025 were reviewed / audited by the then statutory auditor ('Other auditors') of the Transferor Company, who have expressed unmodified opinions vide their reports dated 07 February 2025 and 17 May 2025, respectively. We have relied upon the aforesaid financial information and the reports of the other auditors as aforementioned and as furnished to us by the management for the purpose of our review of the accompanying Statement. We have reviewed the adjustments made by the management consequent to the amalgamation of the Transferor Companies with the Holding Company to arrive at restated comparative financial information for all the periods presented in the accompanying Statement. Our conclusion is not modified in respect of this matter.

**For S R B C & CO LLP**

Chartered Accountants

**ICAI Firm registration number: 324982E/E300003**



**per Anil Jobanputra**

Partner

Membership No.: 110759

UDIN: 26110759CFNUTM3334

Place: Mumbai

Date: February 05, 2026



# **S R B C & C O L L P**

Chartered Accountants

**Viyash Scientific Limited (formerly known as Sequent Scientific Limited)**  
**Page 4 of 4**

### **Annexure 1 to Auditor's report**

#### **Name of the Holding Company**

1. Viyash Scientific Limited

#### **Including its following subsidiaries:**

2. Alivira Animal Health Limited, India
3. Appco Pharma LLC

#### **Including its following subsidiary:**

4. Alivira Animal Health Limited, Ireland

#### **Including its following subsidiaries and sub subsidiaries:**

5. Vila Viña Participacions, S.L.
6. Laboratorios Karizoo, S.A.
7. Phytotherapeutic Solutions S.L.
8. Alivira Saude Animal Ltda
9. Alivira Saude Animal Brasil Participacoes Ltda
10. Expeden Distribuidora De Produtos Veterinarios Ltda
11. Provet Veteriner Ürünleri San. Ve Tic. A.Ş.
12. Topkim Topkapi İlaç premiks Sanayi Ve Ticaret A.Ş.
13. Laboratorios Karizoo, S.A. de C.V. (Mexico)
14. Alivira Animal Health UK Limited
15. Alivira Italia S.R.L.
16. Alivira Animal Health USA LLC
17. Alivira BV
18. N-Vet AB
19. Bremer Pharma GmbH
20. Alivira NV

#### **Including following Trust:**

1. Sequent Scientific Employee Stock Option Plan Trust



# Viyash

VIYASH SCIENTIFIC LIMITED (Formerly known as Sequent Scientific Limited)

Regd. Office: 3rd Floor, Sivalli's Corporate Plot No. 290, Road No. 6, SYN 33 34P TO 39, Gultala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana, India  
E-mail: investorrelations@sequent.in, E-mail: info@viyash.com, Website: www.sequent.in Tel No +91 40 23635000

CIN L99999TS1985PLC196357

## STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

(₹ in Million)

| Sr. No | Particulars   | 3 months ended<br>31-December-<br>2025 | Preceding<br>3 months ended<br>30-September-<br>2025 | Corresponding<br>3 months ended<br>in previous<br>period<br>31-December-<br>2024 | Year to date for<br>current period<br>ended<br>31-December-<br>2025 | Corresponding<br>year to date for<br>previous period<br>ended<br>31-December-<br>2024 | Previous year<br>ended<br>31-March-2025 |
|--------|---|--|--|--|---|---|---|
|        |   | Unaudited                              | Unaudited<br>(Restated)<br>(refer note 4)            | Unaudited<br>(Restated)<br>(refer note 4)  | Unaudited   | Unaudited<br>(Restated)<br>(refer note 4)   | Audited<br>(Restated)<br>(refer note 4) |
| I      | Revenue from operations   | 8,584.10                               | 8,503.00   | 7,740.30   | 25,003.50   | 22,345.30   | 30,068.40                               |
| II     | Other income (refer note 7)   | 139.80                                 | 74.60  | 66.60  | 276.30  | 226.70  | 328.90                                  |
| III    | Total income (I+II)   | 8,723.90                               | 8,577.60   | 7,806.90   | 25,279.80   | 22,572.00   | 30,397.30                               |
| IV     | <b>Expenses</b>   |  |  |  |   |   |   |
|        | (a) Cost of materials consumed  | 3,472.90                               | 3,532.40   | 3,445.90   | 10,130.10   | 9,363.80  | 12,384.70                               |
|        | (b) Purchases of stock-in-trade   | 565.80                                 | 496.80   | 429.40   | 1,585.80  | 1,893.10  | 2,387.70                                |
|        | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | (129.40)                               | (244.70)   | (105.50)   | (216.90)  | (202.90)  | (50.50)                                 |
|        | (d) Employee benefits expense   | 1,376.90                               | 1,392.00   | 1,444.20   | 4,156.80  | 4,145.00  | 5,519.70                                |
|        | (e) Finance costs   | 167.50                                 | 175.10   | 206.40   | 546.90  | 656.90  | 863.70                                  |
|        | (f) Depreciation and amortisation expenses  | 585.30                                 | 591.10   | 583.90   | 1,732.30  | 1,739.80  | 2,387.10                                |
|        | (g) Other expenses  | 1,536.60                               | 1,586.70   | 1,534.30   | 4,689.50  | 4,428.70  | 6,006.80                                |
|        | (h) Net Monetary (gain) / loss on Hyperinflation economy (refer note 8)           | 5.00                                   | 7.50   | (5.40)   | (24.60)   | (22.90)   | (29.30)                                 |
|        | Total expenses (IV)   | 7,580.60                               | 7,536.90   | 7,533.20   | 22,599.90   | 22,001.50   | 29,449.90                               |
| V      | Profit before tax and exceptional items (III-IV)                                  | 1,143.30                               | 1,040.70   | 273.70   | 2,679.90  | 570.50  | 947.40                                  |
| VI     | Exceptional items (refer note 5)  | (412.60)                               | (17.00)  | (28.90)  | (442.10)  | (72.10)   | (815.60)                                |
| VII    | Profit before tax (V-VI)  | 730.70                                 | 1,023.70   | 244.80   | 2,237.80  | 498.40  | 131.80                                  |
| VIII   | <b>Tax expense / (credit)</b>   |  |  |  |   |   |   |
|        | (a) Current tax   | (274.20)                               | 372.70   | 204.90   | 338.60  | 628.60  | 765.20                                  |
|        | (b) Deferred tax  | 519.70                                 | (78.00)  | (379.50)   | 316.50  | (610.20)  | (791.60)                                |
|        | (c) Adjustment of tax pertaining to earlier period                                | -                                      | -  | -  | -   | 0.50  | 0.50                                    |
|        | Total tax expense / (credit) (VIII)   | 245.50                                 | 294.70   | (174.60)   | 655.10  | 18.90   | (25.90)                                 |
| IX     | Profit after tax (VII-VIII)   | 485.20                                 | 729.00   | 419.40   | 1,582.70  | 479.50  | 157.70                                  |
| X      | <b>Other comprehensive income / (loss)</b>  |  |  |  |   |   |   |
|        | Items that will not be reclassified to profit or loss                             |  |  |  |   |   |   |
|        | (a) Re-measurement gain / (loss) on defined benefits plans                        | (5.20)                                 | 0.40   | (1.10)   | (4.80)  | 14.60   | (8.00)                                  |
|        | (b) Fair value gain / (loss) from investment in equity instruments                | 0.10                                   | (0.10)   | (0.10)   | 0.10  | 0.20  | (0.40)                                  |
|        | (c) Income tax relating to items that will not be reclassified to profit or loss  | 0.80                                   | (0.30)   | 2.70   | 0.50  | (3.30)  | 2.60                                    |
|        | Items that will be reclassified to profit or loss                                 |  |  |  |   |   |   |
|        | (a) Exchange differences on translation of foreign operations                     | 92.80                                  | 249.70   | (284.20)   | 566.80  | (282.70)  | 421.60                                  |
|        | (b) Exchange differences on net investment in foreign operations                  | (59.40)                                | 55.00  | (260.00)   | 116.20  | (364.60)  | (265.50)                                |
|        | Total other comprehensive income / (loss) (net of tax)                            | 29.10                                  | 304.70   | (542.70)   | 678.80  | (635.80)  | 150.30                                  |
| XI     | Total comprehensive income / (loss), net of tax (IX+X)                            | 514.30                                 | 1,033.70   | (123.30)   | 2,251.50  | (156.30)  | 308.00                                  |
|        | <b>Profit / (loss) attributable to:</b>   |  |  |  |   |   |   |
|        | - Owners of the Company   | 384.40                                 | 549.10   | 446.10   | 1,251.70  | 494.60  | 232.20                                  |
|        | - Non-controlling interest  | 100.80                                 | 179.90   | (26.70)  | 331.00  | (15.10)   | (74.50)                                 |
|        | <b>Other comprehensive income / (loss) attributable to:</b>                       |  |  |  |   |   |   |
|        | - Owners of the Company   | (1.50)                                 | 219.70   | (533.80)   | 514.40  | (639.50)  | (1.80)                                  |
|        | - Non-controlling interest  | 30.60                                  | 85.00  | (8.90)   | 164.40  | 3.70  | 152.10                                  |
|        | <b>Total comprehensive income / (loss) attributable to:</b>                       |  |  |  |   |   |   |
|        | - Owners of the Company   | 382.90                                 | 768.80   | (87.70)  | 1,766.10  | (144.90)  | 230.40                                  |
|        | - Non-controlling interest  | 131.40                                 | 264.90   | (35.60)  | 495.40  | (11.40)   | 77.60                                   |
| XII    | Equity share capital (face value of ₹ 2 each) (refer note 4)                      | 872.20                                 | 503.30   | 500.50   | 872.20  | 500.50  | 500.60                                  |
| XIII   | Other equity  |  |  |  |   |   | 23,815.30                               |
| XIV    | Earnings per equity share:<br>(face value of ₹ 2 each) (not annualised)           |  |  |  |   |   |   |
|        | (1) Basic in ₹ (refer note 9)   | 0.89                                   | 1.28   | 1.04   | 2.91  | 1.15  | 0.54                                    |
|        | (2) Diluted in ₹ (refer note 9)   | 0.87                                   | 1.26   | 1.01   | 2.87  | 1.13  | 0.53                                    |
|        | See accompanying notes to the unaudited consolidated financial results            |  |  |  |   |   |   |

*A. Srinivas*





VIYASH SCIENTIFIC LIMITED (Formerly known as Sequent Scientific Limited)

Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, Road No. 6, SYN 33 34P TO 39, Gutala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana, India.  
 E-mail: investorrelations@sequent.in, E-mail: info@viyash.com, Website: www.sequent.in Tel No.: +91 40 23635000  
 CIN: L99999TS1985PLC196357

**Notes:**

1. The above unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 05 February 2026.
2. The above unaudited consolidated financial results include results of subsidiaries. The said financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standard ("Ind AS") 34, prescribed under section 133 of the Companies Act 2013 (the "Act") read with the relevant rules issued thereunder and the other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
3. The Board of Directors monitor the business activity as a single segment viz. Pharmaceuticals. The financial results are reflective of the disclosure requirements of Ind AS 108 - Operating Segments.
4. The Board of Directors of the Company at their meeting held on 26 September 2024 have approved the Composite Scheme of Amalgamation (the 'Scheme') amongst the Company, erstwhile Sequent Research Limited (wholly owned subsidiary of the Company), Viyash Life Sciences Private Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, SV Labs Private Limited, Vindhya Organics Private Limited, Genin Life Sciences Private Limited (referred to as 'Transferor Companies') in terms of Section 230-232 and other applicable provisions of Companies Act, 2013.

The Hon'ble National Company Law Tribunal (NCLT), Hyderabad vide its order dated 18 November 2025 sanctioned the Scheme with an Appointed date of 01 April 2025. The Scheme has become effective on 16 December 2025 upon filing of the certified true copy of the order with the Registrar of Companies Hyderabad. The effect of the Scheme has been given in the financial results for the quarter and nine months ended 31 December 2025. As per the terms of the Scheme, the Company has allotted 18,19,21,827 fully paid-up equity shares of face value of ₹ 2 each, as per the share exchange ratio of 56 fully paid-up equity shares of face value of ₹ 2 each of the Company for every 100 fully paid-up equity shares of face value of ₹ 10 each held by eligible shareholders of erstwhile Viyash Life Sciences Private Limited as on the record date. The Company has also allotted 2,03,41,257 warrants under the Scheme to eligible warrant holder of erstwhile Viyash Life Sciences Private Limited as per the Warrant exchange ratio of 56 warrants of the Company for every 100 warrants held in erstwhile Viyash Life Sciences Private Limited and received a consideration of ₹ 925 million during the quarter ended 31 December 2025 (representing 25% on Warrant consideration as per the Scheme).

The Company has accounted for the business combination transaction using the 'Pooling of interest method' as given under Appendix C to Ind AS 103, 'Business Combinations of Entities under Common Control', in accordance with the accounting treatment prescribed in the Scheme. Accordingly, the consolidated financial results of the Group in respect of the preceding / corresponding prior periods have been restated as if the aforesaid business combination had occurred from the beginning of the preceding period (i.e. 01 April 2024) as per below:

| Particulars  | (₹ in Million)                                   |          |  |          |   |           |                                      |           |
|--|--|----------|--|----------|---|-----------|--------------------------------------|-----------|
|  | Preceding<br>3 months ended<br>30-September-2025 |          | Corresponding<br>3 months ended in previous period<br>31-December-2024 |          | Corresponding year to date for previous<br>period ended<br>31-December-2024 |           | Previous year ended<br>31-March-2025 |           |
|  | Reported   | Restated | Reported   | Restated | Reported  | Restated  | Reported                             | Restated  |
| Revenue from operations  | 4,239.90   | 6,503.00 | 3,908.10   | 7,740.30 | 11,496.70   | 22,345.30 | 15,513.70                            | 30,068.40 |
| Profit before tax  | 271.60   | 1,023.70 | 81.00  | 244.80   | 280.00  | 498.40    | 443.10                               | 131.80    |
| Profit / (loss) after tax  | 196.00   | 729.00   | 64.80  | 419.40   | 218.80  | 479.50    | 322.60                               | 157.70    |
| Total comprehensive income / (loss), (net of tax)                        | 339.50   | 1,033.70 | (503.80)   | (123.30) | (464.80)  | (156.30)  | 106.50                               | 308.00    |
| Basic earnings per equity share (in ₹) (not annualised) - Refer Note 9   | 0.59   | 1.28     | 0.14   | 1.04     | 0.50  | 1.15      | 0.88                                 | 0.54      |
| Diluted earnings per equity share (in ₹) (not annualised) - Refer Note 9 | 0.58   | 1.26     | 0.13   | 1.01     | 0.49  | 1.13      | 0.85                                 | 0.53      |

| Particulars   | Note Reference | 3 months ended<br>31-December-2025 | Preceding<br>3 months ended<br>30-September-2025 |                         | Corresponding<br>3 months ended in<br>previous period<br>31-December-2024 | Year to date for<br>current period ended<br>31-December-2025 | Corresponding year<br>to date for previous<br>period ended<br>31-December-2024 | Previous year ended<br>31-March-2025 |
|---|----------------|------------------------------------|--|-------------------------|---|--|--|--------------------------------------|
|   |                |                                    | Unaudited  | Unaudited<br>(Restated) |   | Unaudited  | Unaudited<br>(Restated)  | Unaudited<br>(Restated)              |
|   |                |                                    | Unaudited  | Unaudited<br>(Restated) |   | Unaudited<br>(Restated)                                      | Unaudited<br>(Restated)  | Unaudited<br>(Restated)              |
| Expenses related to Scheme of Amalgamation  | 5(a)           | 412.60                             | 17.00  | 28.90                   | 442.10  | 72.10  | 78.50  | 40.00                                |
| One time settlement cost  | 5(b)           | -                                  | -  | -                       | -   | -  | -  | (35.80)                              |
| (Reversal) / Expenses related to operations restructuring drive                             | 5(c)           | -                                  | -  | -                       | -   | -  | -  | (7.10)                               |
| Insurance claim received related to cyber-attack incident at N-VET AB (overseas subsidiary) | 5(d)           | -                                  | -  | -                       | -   | -  | -  | 740.00                               |
| Provision for performance incentive   | 5(e)           | -                                  | -  | -                       | -   | -  | -  | 815.60                               |
| <b>Total</b>  |                | <b>412.60</b>                      | <b>17.00</b>                                     | <b>28.90</b>            | <b>442.10</b>   | <b>72.10</b>   | <b>78.50</b>   | <b>40.00</b>                         |

5(a) The Company has recorded below transaction costs pertaining to Scheme:

- (i) Stamp duty recognized on estimated basis amounting to ₹ 295.50 million for quarter and nine-months period ended 31 December 2025 payable pursuant to scheme.
- (ii) Transaction costs with respect to fees payable to merchant banker in relation to Scheme amounting to ₹ 90.50 million and ₹ 107.60 million for quarter and nine-months period ended 31 December 2025.
- (iii) Other transaction costs with respect to fees payable to lawyers and other consultants engaged in relation to the Scheme amounting to ₹ 25.60 million and ₹ 38 million for the quarter and nine-months period ended 31 December 2025.

5(b) During the previous year ended 31 March 2025, Alivira Animal Health Limited ("AAHL") a wholly owned subsidiary of the Company, had made provision for one-time settlement of the disputes in relation to its leasehold land situated at Visakhapatnam.

5(c) During the previous year ended 31 March 2025, based on confirmation from vendor, the Group reversed provision related to domain expert advisory fees towards revamping of manufacturing and procurement processes.

5(d) During the previous year ended 31 March 2025, the Group has received insurance claim related to cyber-attack incident which had occurred at its overseas subsidiary N-VET AB in Sweden.

5(e) During the previous year ended 31 March 2025, the Group had recorded provision for one time performance incentive payable to a Key Managerial Personnel as approved by the Board of Directors of erstwhile Viyash Life Sciences Private Limited.





VIYASH SCIENTIFIC LIMITED (Formerly known as Sequent Scientific Limited)

Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, Road No. 6, SYN 33 34P TO 39, Gullala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana, India.  
E-mail: investorrelations@sequent.in, E-mail: info@viyash.com, Website: www.sequent.in Tel No.: +91 40 23635000  
CIN: L99999TS1985PLC196357

6. The Government of India has implemented four new labour codes ("New Labour Codes"), including the Code on Wages, 2019, effective from 21 November 2025. The Government is in the process of issuing related rules. The Company has assessed the implications of the New Labour Codes considering uniform definition of "wages" as per the New Labour Codes and has estimated impact of ₹ 12 million on account of New labour Codes and recorded it in employee benefit expenses in the financial results. The Company continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards.

7. During the current quarter ended 31 December 2025, the Group has recorded profit of ₹ 43 million under the head 'Other Income' on completion of on sale of land, building and other assets held at one of its manufacturing facility at Parwada, Visakhapatnam which was classified as 'Assets held for sale'.

8. The Group has applied IND AS 29 'Accounting for Hyperinflationary economies' on Turkish subsidiaries, since the Turkish Lira is a functional currency of these subsidiaries in Turkey which is a hyperinflationary economy. In preparing the consolidated financial results, the non-monetary assets (includes goodwill, property, plant and equipment, etc.), liabilities, owner's equity and statement of profit and loss of the aforesaid subsidiaries have been restated to the measuring unit current as on the reporting date by applying general price index of the Turkish economy. Considering that the presentation currency of consolidated financial results is ₹, the restatement of comparative figures in consolidated financial results is not required.

9. Weighted average number of shares considered for calculation of basic and diluted earnings per share for all the periods reported includes the weighted average effect of equity shares and warrants allotted pursuant to the Scheme as described in note 4 above and outstanding share options under employees share option plan.

For Viyash Scientific Limited  
(Formerly known as Sequent Scientific Limited)

  
Dr. Hari Babu Boopathy  
Managing Director & Group CEO

Hyderabad, 05 February 2026



**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended****Review Report to****The Board of Directors****Viyash Scientific Limited (formerly known as Sequent Scientific Limited)**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Viyash Scientific Limited (formerly known as Sequent Scientific Limited) (the "Company") which includes Sequent Scientific Employee Stock Option Plan Trust (the "Trust") for the quarter ended December 31, 2025 and year to date from April 01, 2025 to December 31, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We draw attention to Note 4 to the accompanying Statement, which describes that pursuant to the Composite Scheme of Amalgamation (the "Scheme") between the Company and SeQuent Research Limited, Viyash Life Sciences Private Limited and its subsidiaries (individually referred to as "Transferor Company"), as approved by the Hon'ble National Company Law Tribunal vide its order dated November 18, 2025, the Transferor Companies have been amalgamated with the Company. The amalgamation has been accounted for in the manner as prescribed under the Scheme and in accordance with Appendix C of Ind AS 103 - Business Combinations, applicable to business combination of entities under common control. Accordingly, the comparative financial information for the quarter ended 30 September 2025, quarter / period ended 31 December 2024 and year ended 31 March 2025 presented in accompanying Statement, has been restated to give effect to the aforesaid amalgamation, as described further in the said note. Our conclusion is not modified in respect of this matter.



**Viyash Scientific Limited (formerly known as Sequent Scientific Limited)****Page 2 of 2**

6. The comparative Ind AS financial information presented in the accompanying Statement includes the financial information of Viyash Life Sciences Private Limited and its subsidiaries for the quarter / period ended 31 December 2024 and for the year ended 31 March 2025 were reviewed / audited by the then statutory auditor ('Other auditors') of the Transferor Company, who have expressed unmodified opinions vide their reports dated 07 February 2025 and 17 May 2025, respectively. We have relied upon the aforesaid financial information and the reports of the Other auditors as aforementioned and as furnished to us by the management for the purpose of our review of the accompanying Statement. We have reviewed the adjustments made by the management consequent to the amalgamation of the Transferor Companies with the Company to arrive at restated comparative financial information for all the periods presented in the accompanying Statement. Our conclusion is not modified in respect of this matter.
7. The accompanying Statement includes unaudited interim financial results and other financial information in respect of Sequent Scientific Employee Stock Option Plan Trust, whose interim financial results and other financial information reflect total revenues of Rs. Nil and Rs. Nil, total net (loss) / profit after tax of Rs. (0.01 million) and Rs. 0.02 million, total comprehensive (expense) / income of Rs. (0.01 million) and Rs. 0.02 million for the quarter ended December 31, 2025 and period ended on that date respectively.

These unaudited interim financial results and other unaudited financial information of the Trust have not been reviewed by any auditors and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of the Trust is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results and other unaudited financial information of the Trust are not material to the Company.

Our conclusion on the Statement in respect of matter stated in paragraph 7 above is not modified with respect to our reliance on the financial results certified by the Management.

**For S R B C & CO LLP**  
Chartered Accountants  
**ICAI Firm registration number:** 324982E/E300003



per Anil Jobanputra  
Partner  
Membership No.: 110759  
UDIN: 26110759EORWFA6017  
Place: Mumbai  
Date: February 05, 2026



# Viyash

## VIYASH SCIENTIFIC LIMITED (Formerly known as Sequent Scientific Limited)

Regd. Office 3rd Floor, Srivalli's Corporate, Plot No. 290 Road No. 6, SYN 33 34P To 39, Guttala Begumpet, Jubilee Hills, Nalgonda, Hyderabad-500033, Telangana, India  
E-mail: investorrelations@sequent.in, E-mail: info@viyash.com, Website: www.sequent.in Tel No +91 40 23635000  
CIN L99999TS1985PLC196357

## STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

(₹ in Million)

| Sr. No. | Particulars   | 3 months ended<br>31-December-2025 | Preceding<br>3 months ended<br>30-September-2025 | Corresponding<br>3 months ended in previous<br>period<br>31-December-2024 | Year-to-date for current<br>period ended<br>31-December-2025 | Corresponding year to<br>date for previous period<br>ended<br>31-December-2024 | Year ended<br>31-March-2025             |
|---------|---|------------------------------------|--|---|--|--|---|
|         |   | Unaudited                          | Unaudited<br>(Restated)<br>(refer note 4)        | Unaudited<br>(Restated)<br>(refer note 4)                                 | Unaudited  | Unaudited<br>(Restated)<br>(refer note 4)                                      | Audited<br>(Restated)<br>(refer note 4) |
| I       | Revenue from operations   | 3,416.40                           | 3,397.50   | 3,380.50  | 10,095.70  | 9,660.20   | 13,103.40                               |
| II      | Other income (refer note 6)   | 162.90                             | 173.20   | 159.70  | 465.10   | 527.00   | 722.10                                  |
| III     | <b>Total income (I+II)</b>  | <b>3,579.30</b>                    | <b>3,570.70</b>                                  | <b>3,540.20</b>   | <b>10,560.80</b>   | <b>10,187.20</b>   | <b>13,825.50</b>                        |
| IV      | <b>Expenses</b>   |                                    |  |   |  |  |   |
|         | (a) Cost of materials consumed  | 1,550.30                           | 1,559.90   | 1,572.40  | 4,436.60   | 4,304.60   | 5,650.80                                |
|         | (b) Purchases of stock-in-trade   | 54.40                              | 45.40  | 11.10   | 102.00   | 235.80   | 344.80                                  |
|         | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | (96.60)                            | (60.20)  | (53.00)   | (3.20)   | (170.30)   | (86.10)                                 |
|         | (d) Conversion and processing charges   | 6.40                               | 10.70  | 9.80  | 31.20  | 49.90  | 70.60                                   |
|         | (e) Employee benefits expenses  | 501.00                             | 523.90   | 535.70  | 1,563.00   | 1,611.00   | 2,158.50                                |
|         | (f) Finance costs   | 35.60                              | 41.00  | 59.10   | 136.80   | 193.70   | 251.40                                  |
|         | (g) Depreciation and amortisation expenses  | 312.00                             | 309.00   | 318.10  | 929.90   | 942.50   | 1,247.20                                |
|         | (h) Other expenses  | 697.50                             | 797.30   | 721.70  | 2,247.70   | 2,154.20   | 2,881.90                                |
|         | <b>Total expenses (IV)</b>  | <b>3,060.60</b>                    | <b>3,227.00</b>                                  | <b>3,174.90</b>   | <b>9,444.00</b>  | <b>9,321.40</b>  | <b>12,519.10</b>                        |
| V       | <b>Profit before tax and exceptional items (III-IV)</b>                           | <b>518.70</b>                      | <b>343.70</b>                                    | <b>365.30</b>   | <b>1,116.80</b>  | <b>865.80</b>  | <b>1,306.40</b>                         |
| VI      | Exceptional items (refer note 5)  | (412.60)                           | (17.00)  | (28.90)   | (442.10)   | (72.10)  | (814.70)                                |
| VII     | <b>Profit before tax (V-VI)</b>   | <b>106.10</b>                      | <b>326.70</b>                                    | <b>336.40</b>   | <b>674.70</b>  | <b>793.70</b>  | <b>491.70</b>                           |
| VIII    | <b>Tax expense / (credit)</b>   |                                    |  |   |  |  |   |
|         | (a) Current tax   | (256.90)                           | 147.10   | 124.00  | 2.30   | 377.20   | 396.90                                  |
|         | (b) Deferred tax  | 363.80                             | (48.80)  | (298.90)  | 271.80   | (362.10)   | (490.10)                                |
|         | (c) Adjustment of tax relating to earlier periods                                 |                                    |  |   |  |  |   |
|         | <b>Total tax expense / (credit) (VIII)</b>  | <b>106.90</b>                      | <b>98.30</b>                                     | <b>(174.90)</b>   | <b>274.10</b>  | <b>15.10</b>   | <b>(93.20)</b>                          |
| IX      | <b>Profit / (Loss) after tax (VII-VIII)</b>                                       | <b>(0.80)</b>                      | <b>228.40</b>                                    | <b>511.30</b>   | <b>400.60</b>  | <b>778.60</b>  | <b>584.90</b>                           |
| X       | <b>Other comprehensive income / (Loss)</b>  |                                    |  |   |  |  |   |
|         | Items that will not be reclassified to profit or loss                             |                                    |  |   |  |  |   |
|         | (a) Re-measurement gain / (loss) on defined benefits plans                        | (3.40)                             | 1.00   | (1.00)  | (2.40)   | 17.40  | (3.80)                                  |
|         | (b) Fair value gain / (loss) from investment in equity instruments                | 0.10                               | (0.10)   | (0.10)  | 0.10   | 0.20   | (0.40)                                  |
|         | (c) Income tax relating to items that will not be reclassified to profit or loss  | 0.80                               | (0.30)   | 0.80  | 0.50   | (4.30)   | 1.00                                    |
|         | <b>Total other comprehensive income / (Loss) (net of tax)</b>                     | <b>(2.50)</b>                      | <b>0.60</b>                                      | <b>(0.30)</b>   | <b>(1.80)</b>  | <b>13.30</b>   | <b>(3.20)</b>                           |
| XI      | <b>Total comprehensive income/(Loss), net of tax (IX+X)</b>                       | <b>(3.30)</b>                      | <b>229.00</b>                                    | <b>511.00</b>   | <b>398.80</b>  | <b>791.90</b>  | <b>581.70</b>                           |
| XII     | Equity share capital (face value of ₹ 2 each) (refer note 4)                      | 872.20                             | 503.30   | 500.50  | 672.20   | 500.50   | 500.60                                  |
| XIII    | Other equity  |                                    |  |   |  |  | 28,583.50                               |
| XIV     | <b>Earnings per equity share: (face value of ₹ 2 each)<br/>(not annualised)</b>   |                                    |  |   |  |  |   |
|         | (1) Basic in ₹ (refer note 8)   | (0.00)                             | 0.53   | 1.20  | 0.93   | 1.82   | 1.36                                    |
|         | (2) Diluted in ₹ (refer note 8)   | (0.00)                             | 0.52   | 1.17  | 0.92   | 1.78   | 1.34                                    |
|         | See accompanying notes to unaudited standalone financial results                  |                                    |  |   |  |  |   |



# Viyash

VIYASH SCIENTIFIC LIMITED (Formerly known as Sequent Scientific Limited)

Regd. Office: 3rd Floor, Sivali's Corporate Plot No. 290 Road No. 6, SYN 33 34P TO 39, Gutta Begumpet, Jubilee Hills, Shukpet, Hyderabad-500033, Telangana, India  
E-mail: investorsrelations@sequent.in, E-mail: info@viyash.com, Website: www.sequent.in, Tel No: +91 40 23635000

## STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

### Notes:

- The above unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 05 February 2026.
- The Standalone financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standard ("Ind AS") 34, prescribed under section 133 of the Companies Act 2013 (the "Act") read with the relevant rules issued thereunder and the other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- As the Board of Directors monitors the business activity as a single segment viz. Pharmaceuticals, the financial results are reflective of the disclosure requirements of Ind AS 108 - Operating Segments.
- The Board of Directors of the Company at their meeting held on 26 September 2024 have approved the Composite Scheme of Amalgamation (the Scheme) amongst the Company, Sequent Research Limited (wholly owned subsidiary of the Company), Viyash Life Sciences Private Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, SV Labs Private Limited, Vindhya Organics Private Limited, Genin Life Sciences Private Limited (referred to as 'Transferor Companies') in terms of Section 230-232 and other applicable provisions of Companies Act, 2013.

The Hon'ble National Company Law Tribunal (NCLT), Hyderabad vide its order dated 18 November 2025 sanctioned the Scheme with an Appointed date of 01 April 2025. The Scheme has become effective on 16 December 2025 upon filing of the certified true copy of the order with the Registrar of Companies Hyderabad. The effect of the Scheme has been given in the financial results for the quarter and nine months ended 31 December 2025. As per the terms of the Scheme, the Company has allotted 18,19,21,827 fully paid-up equity shares of face value of ₹ 2 each, as per the share exchange ratio of 56 fully paid-up equity shares of face value of ₹ 2 each of the Company for every 100 fully paid-up equity shares of face value of ₹ 10 each held by eligible shareholders of erstwhile Viyash Life Sciences Private Limited as on the record date. The Company has also allotted 2,03,41,257 warrants under the Scheme to eligible warrant holder of erstwhile Viyash Life Sciences Private Limited as per the Warrant exchange ratio of 50 warrants of the Company for every 100 warrants held in erstwhile Viyash Life Sciences Private Limited and received a consideration of ₹ 925 million during the quarter ended 31 December 2025 (representing 25% on Warrant consideration as per the Scheme).

The Company has accounted for the business combination transaction using the 'Pooling of interest method' as given under Appendix C to Ind AS 103 'Business Combinations of Entities under Common Control', in accordance with the accounting treatment prescribed in the Scheme. Accordingly, the financial results of the company in respect of the preceding / corresponding prior periods have been restated as if the aforesaid business combination had occurred from the beginning of the preceding period (i.e. 01 April 2024) as per below.

### Details of revenue and profit restated due to the Scheme of Amalgamation

| Particulars  | Preceding 3 months ended 30-September-2025 |          | Corresponding 3 months ended in previous period 31-December-2024 |          | Corresponding year to date for previous period ended 31-December-2024 |          | Previous year ended 31-Mar-2025 |           |
|--|--|----------|--|----------|---|----------|---------------------------------|-----------|
|  | Reported                                   | Restated | Reported   | Restated | Reported  | Restated | Reported                        | Restated  |
| Revenue from operations  | 340.30                                     | 3,397.50 | 362.70   | 3,380.50 | 1,359.30  | 9,660.20 | 1,782.60                        | 13,103.40 |
| Profit before tax  | 43.40                                      | 326.70   | 36.80  | 336.40   | 161.40  | 793.70   | 220.50                          | 491.70    |
| Profit after tax   | 30.80                                      | 228.40   | 28.10  | 511.30   | 115.70  | 778.80   | 158.00                          | 584.90    |
| Total comprehensive income, (net of tax)                                 | 31.50                                      | 229.00   | 28.00  | 511.00   | 115.30  | 791.90   | 156.50                          | 581.70    |
| Basic earnings per equity share (in ₹) (not annualised) - Refer Note 8   | 0.12                                       | 0.53     | 0.11   | 1.20     | 0.46  | 1.82     | 0.63                            | 1.36      |
| Diluted earnings per equity share (in ₹) (not annualised) - Refer Note 8 | 0.12                                       | 0.52     | 0.11   | 1.17     | 0.45  | 1.78     | 0.62                            | 1.34      |

### 5 Exceptional items includes

| Particulars  | Note reference | 3 months ended 31-December-2025 | Preceding 3 months ended 30-September-2025 | Corresponding 3 months ended in previous period 31-December-2024 | Year to date for current period ended 31-December-2025 | Corresponding year to date for previous period ended 31-December-2024 | Year ended 31-March-2025 |
|--|----------------|---------------------------------|--|--|--|---|--------------------------|
|  |                | Reported                        | Restated                                   | Reported   | Restated   | Reported  | Restated                 |
|  |                | Unaudited                       | Unaudited (Restated)                       | Unaudited (Restated)   | Unaudited  | Unaudited (Restated)  | Audited (Restated)       |
| Expenses related to the Scheme of Amalgamation (Reversal) / Expenses related to operations restructuring drive | 5 (a)          | 412.60                          | 17.00                                      | 28.90  | 442.10   | 72.10   | 78.50                    |
| Provision for performance incentive  | 5 (b)          | —                               | —  | —  | —  | —   | (3.80)                   |
| <b>Total</b>   | <b>5 (c)</b>   | <b>412.60</b>                   | <b>17.00</b>                               | <b>28.90</b>   | <b>442.10</b>  | <b>72.10</b>  | <b>814.70</b>            |

S(a) The Company has recorded below transaction costs pertaining to Scheme

- Stamp duty recognized on estimated basis amounting to ₹ 296.50 million for quarter and nine-months period ended 31 December 2025 payable pursuant to scheme.
- Transactions costs with respect to fees payable to merchant banker in relation to Scheme amounting to ₹ 90.50 million and ₹ 107.60 million for quarter and nine-months period ended 31 December 2025.
- Other transaction costs with respect to fees payable to lawyers and other consultants engaged in relation to the Scheme amounting to ₹ 25.60 million and ₹ 38 million for the quarter and nine-months period ended 31 December 2025.

S(b) During the previous year ended 31 March 2025, based on confirmation from vendor, the Company reversed provision related to domain expert advisory fees towards revamping of manufacturing and procurement processes

S(c) During the previous year ended 31 March 2025, the Company had recorded provision for one time performance incentive payable to a Key Managerial Personnel as approved by the Board of Directors of erstwhile Viyash Life Sciences Private Limited

6 During the current quarter ended 31 December 2025, the Company has recorded profit of ₹ 43 million under the head 'Other Income' on completion of on sale of land, building and other assets held at one of its manufacturing facility at Parwada, Visakhapatnam which was classified as 'Assets held for sale'

7 The Government of India has implemented four new labour codes ("New Labour Codes"), including the Code on Wages, 2019, effective from 21 November 2025. The Government is in the process of issuing related rules. The Company has assessed the implications of the New Labour Codes considering uniform definition of 'wages' as per the New Labour Codes and has estimated impact of ₹ 2.30 million on account of New Labour Codes and recorded it in employee benefit expenses in the financial results. The Company continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards

8 Weighted average number of shares considered for calculation of basic and diluted earnings per share for all the periods reported includes the weighted average effect of equity shares and warrants allotted pursuant to the Scheme as described in note 4 above and outstanding share options under employees share option plan

For Viyash Scientific Limited  
(Formerly known as Sequent Scientific Limited)

Dr. Hari Babu Bodupudi  
Managing Director and Group CEO

Hyderabad, 05 February 2026



## Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)

Registered Office:

3<sup>rd</sup> Floor, Srivalli's Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033

T: +91 40 23635000, E:info@viyash.com

E: investorrelations@viyash.com

Website: www.viyash.com

CIN: L99999TS1985PLC196357

### Annexure I

#### Disclosure details in relation to approval of Viyash Scientific Limited Employee Stock Option Scheme 2026

| Sr No. | Particulars   | Description   |
|--------|---|---|
| 1      | Brief details of options granted  | <ul style="list-style-type: none"> <li>➤ The Composite Scheme of Amalgamation ("Scheme") was approved by the NCLT <i>vide</i> order dated November 18, 2025.</li> <li>➤ The Scheme lays down that upon coming into effect, all the stock options granted to employees of Viyash Life Sciences Private Limited ("VLSPL") under the ESOP plan of VLSPL, shall get cancelled and the Company shall adopt and implement a new stock option plan.</li> <li>➤ The total number of stock options proposed to be granted under the ESOP 2026 shall not exceed 2.8% of the post amalgamation paid-up share capital on a fully diluted basis i.e. 1,34,75,000 stock options.</li> <li>➤ The existing grantees shall be eligible for 56 options under ESOP 2026 for every 100 options granted under ESOP plan of VLSPL</li> <li>➤ The balance after adjusting the aforesaid grants shall be utilised by the Nomination and Remuneration Committee of the Company for granting options to eligible employees of VLSPL as per the terms of ESOP 2026, subject to necessary approvals, as may be applicable.</li> </ul> |
| 2      | Whether the scheme is in terms of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 (if applicable) | Yes.  |
| 3      | Total number of shares covered by these options   | Total number of shares covered by the Options is 1,34,75,000.   |
| 4      | Pricing formula   | The exercise price per Option shall be such as may be determined by the Nomination and Remuneration Committee ("NRC") at the time of grant. The specific exercise price shall be specified in the letter to be issued at the time of the grant and shall not be less than the face value of the equity share as on date of grant of such Option.  |
| 5      | Options vested  | 14,41,906 options as per old ESOP plan of VLSPL   |
| 6      | Time within which options may be exercised  | The Vested Options may be exercised at any time within the period determined by the NRC from time to time subject to a maximum period of 24 months from the date of Vesting of the respective Options.  |
| 7      | Options exercised   | Not applicable at this stage  |
| 8      | Money realized by exercise of options   | Not applicable at this stage  |
| 9      | The total number of shares arising as a result of exercise of option  | Not applicable at this stage  |
| 10     | Options lapsed  | Not applicable at this stage  |
| 11     | Variation of terms of options   | Not applicable at this stage  |

## Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)

Registered Office:

3<sup>rd</sup> Floor, Srivalli's Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033

T: +91 40 23635000, E:info@viyash.com

E: investorrelations@viyash.com

Website: www.viyash.com

CIN: L99999TS1985PLC196357

|    |  |  |
|----|--|--|
| 6  | Brief details of significant terms   | <ul style="list-style-type: none"> <li>➤ The NRC is authorised to determine the terms of grant of options, quantum of options, vesting criteria, vesting period etc. to the employees.</li> <li>➤ The total number of stock options proposed to be granted under the ESOP 2026 shall not exceed 2.8% of the post amalgamation paid-up share capital on a fully diluted basis i.e. 1,34,75,000 stock options.</li> <li>➤ The Vesting period shall be minimum 1 year from the grant date.</li> <li>➤ Exercise period shall be 24 months from the date of vesting of respective options.</li> <li>➤ Vesting criteria may comprise of time-based vesting, performance-based vesting (based on the parameters as may be determined by NRC), or a combination of both as mentioned in the Grant Letter.</li> <li>➤ The exercise price per Option shall be such as may be determined by the NRC at the time of grant. The specific exercise price shall be specified in the letter to be issued at the time of the grant and shall not be less than the face value of the equity share as on date of grant of such Option.</li> </ul> |
| 13 | Subsequent changes or cancellation or exercise of such options                       | Not applicable at this stage   |
| 14 | Diluted earnings per share pursuant to issue of equity shares on exercise of options | Not applicable at this stage   |

## Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)

Registered Office:

3<sup>rd</sup> Floor, Srivalli's Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033

T: +91 40 23635000, E:info@viyash.com

E: investorrelations@viyash.com

Website: www.viyash.com

CIN: L99999TS1985PLC196357

### Annexure II

| Sr No. | Particulars   | Mr. Attanti Veera Venkata Srinivasa Rao  | Mr. Nrusimha Srinivasa Rao Bondalapati   | Mr. Peddanna Gumudavelli  | Mr. Pradip Natarajan  |
|--------|---|--|--|---|---|
| 1      | Reason for change viz., appointment, resignation, removal, death or otherwise                     | Appointment as SMP, due to post merger review of leadership roles.   | Appointment as SMP, due to post merger review of leadership roles.   | Appointment as SMP, due to post merger review of leadership roles.  | Change in SMP, due to post merger review of leadership roles. |
| 2      | Date of Appointment/reappointment/cessation (as applicable) and term of appointment/reappointment | February 05, 2026  | February 05, 2026  | February 05, 2026   | February 05, 2026   |
| 3      | Brief Profile (in case of appointment)  | Attanti Veera Venkata Srinivas Rao did his P.G in Organics Chemistry from A P S University. He has over 32 years of pharmaceutical experience across API R&D. Prior to joining Viyash, Attanti Veera Venkata Srinivas Rao worked for over 12 years at Mylan Laboratories Limited, where his role was as Associate Vice-President API R&D. Before that, he worked for over 11 years at Torrent Pharmaceuticals Limited, serving as Assistant General Manager API R&D. | B.N. Srinivasa Rao did his M.Sc from Dr. Baba Saheb Ambedkar Marathwada University. He has over 25 years of pharmaceutical experience across API Quality & Regulatory Affairs roles. Prior to joining Viyash, B. N. Srinivasa Rao worked for over 8 years at Symed Labs Limited, where his last role was Senior General Manager – Quality & Regulatory Affairs (API). Before that, he worked for over 2.5 years at AUCTUS Pharma Limited, serving most recently as Manager – Quality & Regulatory Affairs (API). He also worked for over 1.5 years at Inogent Laboratories | Peddanna Gumudavelli, M. Pharm, RPh, is the Chief Operating Officer of Appco Pharma LLC, US. He is a seasoned professional in the pharma domain. He is having rich experience of 38 years in Pharmaceutical Industry in US and India. He oversees all business operations at Appco Pharma LLC. Strategist with vision of ahead of others. Experienced in development of complex and various generic dosage forms. | Not Applicable  |



## Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)

Registered Office:

3<sup>rd</sup> Floor, Srivalli's Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033

T: +91 40 23635000, E:info@viyash.com

E: investorrelations@viyash.com

Website: www.viyash.com

CIN: L99999TS1985PLC196357

|   |  |   |  |   |                |
|---|--|---|--|---|----------------|
|   |  | <p>At Viyash, for the past 5 years, he has been serving as Vice-President of API R&amp;D.</p> | <p>Pvt. Ltd. (a GVK Bio company) as Deputy Manager – QA &amp; RA (API). Earlier in his career, he spent over 5 years at HETERO Drugs Ltd., where his last role was Manager – QA &amp; RA (API), and over 3 years at Aurobindo Pharma Ltd., where he served as Executive – QA (API).</p> <p>At Viyash, he is responsible for the overall API Quality &amp; Regulatory Affairs across all units.</p> | <p>Accredited with patents in pharmaceutical dosage forms. Involved in successful filing and obtaining approvals of drug products in various Regulated and ROW markets. He is accredited with many of the 'First to File' applications with USFDA and obtained approvals. Trained many people into successful pharmaceutical carriers. He graduated from University College of Pharmaceutical Sciences, Warangal and is a practicing Registered Pharmacist in US.</p> |                |
| 4 | Disclosure of relationships between directors (in case of appointment of a director) | Not Applicable  | Not Applicable   | Not Applicable  | Not Applicable |